Edison Investment Research - CASI Pharmaceuticals (CASI) CASI Pharmaceuticals - New drug licensed targeting antibody checkpoints

Report

Edison Investment Research

Sean Conroy

CASI Pharmaceuticals - New drug licensed targeting antibody checkpoints

CASI announced that it has in licensed the Greater Chinese rights to BI-1206 from BioInvent, which is being investigated in Phase I trials for the treatment of non-Hodgkin lymphoma (NHL) and solid tumors. The drug has a novel target FcγRIIB, an antibody receptor on leukocytes with checkpoint-like properties. The drug is currently in two dose escalation studies for NHL and solid tumors in combination with rituximab and Keytruda, respectively.

28/10/2020 5 EN

Underlying

CASI Pharmaceuticals

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.

See profile

US14757U1097 NASDAQ Stock Market United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

CASI Pharmaceuticals Inc: 1 director

A director at CASI Pharmaceuticals Inc bought 55,573 shares at 4.133USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Free Trial

September 9, 2022 September 9, 2022 1 EN

Edison Investment Research

CASI Pharmaceuticals - Termination of coverage

Edison Investment Research is terminating coverage on Hepion Pharmaceuticals (HEPA), Hurricane Energy (HUR), CASI Pharmaceuticals (CASI) and Monarch Mining Corporation (GBAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

September 23, 2021 September 23, 2021 2 EN

Edison Investment Research

CASI Pharmaceuticals - Termination of coverage

September 23, 2021 September 23, 2021 2 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

16h / 19m 16h / 19m 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

18h / 13m 18h / 13m 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

19h / 40m 19h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CASI Pharmaceuticals - New drug licensed targeting antibody checkpoints

CASI Pharmaceuticals Inc: 1 director

CASI Pharmaceuticals - Termination of coverage

CASI Pharmaceuticals - Termination of coverage

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe